285 related articles for article (PubMed ID: 12942316)
1. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.
Mantha AJ; McFee KE; Niknejad N; Goss G; Lorimer IA; Dimitroulakos J
J Cancer Res Clin Oncol; 2003 Nov; 129(11):631-41. PubMed ID: 12942316
[TBL] [Abstract][Full Text] [Related]
2. Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal.
Niknejad N; Gorn-Hondermann I; Ma L; Zahr S; Johnson-Obeseki S; Corsten M; Dimitroulakos J
Int J Cancer; 2014 Jan; 134(2):268-79. PubMed ID: 23824972
[TBL] [Abstract][Full Text] [Related]
3. Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
Dimitroulakos J; Marhin WH; Tokunaga J; Irish J; Gullane P; Penn LZ; Kamel-Reid S
Neoplasia; 2002; 4(4):337-46. PubMed ID: 12082550
[TBL] [Abstract][Full Text] [Related]
4. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Mantha AJ; Hanson JE; Goss G; Lagarde AE; Lorimer IA; Dimitroulakos J
Clin Cancer Res; 2005 Mar; 11(6):2398-407. PubMed ID: 15788691
[TBL] [Abstract][Full Text] [Related]
5. Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.
Dimitroulakos J; Lorimer IA; Goss G
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4426s-4431s. PubMed ID: 16857822
[TBL] [Abstract][Full Text] [Related]
6. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins.
Zhao TT; Le Francois BG; Goss G; Ding K; Bradbury PA; Dimitroulakos J
Oncogene; 2010 Aug; 29(33):4682-92. PubMed ID: 20562912
[TBL] [Abstract][Full Text] [Related]
7. Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
Ma L; Niknejad N; Gorn-Hondermann I; Dayekh K; Dimitroulakos J
PLoS One; 2012; 7(9):e46055. PubMed ID: 23029387
[TBL] [Abstract][Full Text] [Related]
8. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Dimitroulakos J; Ye LY; Benzaquen M; Moore MJ; Kamel-Reid S; Freedman MH; Yeger H; Penn LZ
Clin Cancer Res; 2001 Jan; 7(1):158-67. PubMed ID: 11205904
[TBL] [Abstract][Full Text] [Related]
9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Shintani S; Kiyota A; Mihara M; Sumida T; Kayahara H; Nakashiro K; Hamakawa H
Am J Clin Oncol; 2003 Oct; 26(5):e150-6. PubMed ID: 14528090
[TBL] [Abstract][Full Text] [Related]
11. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
13. Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.
Tepper SR; Zuo Z; Khattri A; Heß J; Seiwert TY
Oral Oncol; 2016 May; 56():62-70. PubMed ID: 27086488
[TBL] [Abstract][Full Text] [Related]
14. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
[TBL] [Abstract][Full Text] [Related]
15. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
Dayekh K; Johnson-Obaseki S; Corsten M; Villeneuve PJ; Sekhon HS; Weberpals JI; Dimitroulakos J
Mol Cancer Ther; 2014 Nov; 13(11):2559-71. PubMed ID: 25189541
[TBL] [Abstract][Full Text] [Related]
16. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
17. EGFR codon 497 polymorphism - implications for receptor sensitivity to inhibitors in HNSCC cell lines.
Krohn V; Wiegand S; Werner JA; Mandic R
Anticancer Res; 2011 Jan; 31(1):59-65. PubMed ID: 21273581
[TBL] [Abstract][Full Text] [Related]
18. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
19. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
Matheny KE; Barbieri CE; Sniezek JC; Arteaga CL; Pietenpol JA
Laryngoscope; 2003 Jun; 113(6):936-9. PubMed ID: 12782800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
